Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib

RATIONAL: Cisplatin based cancer therapy is an affordable and effective standard therapy for several solid cancers, including lung, ovarian and head and neck cancers. However, the clinical use of cisplatin is routinely limited by the development of drug resistance and subsequent therapeutic failure....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Mortensen, Anja Charlotte Lundgren, Mohajershojai, Tabassom, Hariri, Mehran, Pettersson, Marika, Spiegelberg, Diana
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7554556/
https://ncbi.nlm.nih.gov/pubmed/33102211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.532285
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars